MRI-Guided Radiation Therapy for Breast Cancer
(PPI Trial)
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more information.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the idea that MRI-Guided Radiation Therapy for Breast Cancer is an effective treatment?
The available research shows that MRI-Guided Radiation Therapy for Breast Cancer can be effective because it helps to reduce the amount of healthy tissue exposed to radiation. This is important because it can lower the risk of side effects. For example, one study found that using MRI guidance in a prone position (lying face down) can reduce the radiation dose to the heart and lungs, which is beneficial for patients with left-sided breast cancer. Another study highlights that MRI guidance can improve the visibility of the tumor, allowing for more precise targeting and potentially better outcomes. Compared to traditional methods, MRI guidance can also reduce the number of treatment sessions needed, which can be more convenient for patients.12345
What data supports the effectiveness of MRI-guided radiation therapy for breast cancer?
Research shows that MRI-guided radiation therapy can improve the precision of targeting tumors, reducing the amount of healthy tissue exposed to radiation. This approach, especially in the prone position, can lower the risk of damage to the heart and lungs, which is particularly beneficial for left-sided breast cancer.12345
What safety data is available for MRI-guided radiation therapy for breast cancer?
The safety data for MRI-guided radiation therapy for breast cancer includes studies on the risk of radiation-induced secondary malignancies with partial breast irradiation using a 1.5 T MR-linac, which highlights potential long-term toxicities. Additionally, prone positioning for whole breast irradiation has been shown to result in lower toxicity and reduced lung and heart doses compared to supine positioning. MRI-guided stereotactic accelerated partial breast irradiation (MRgS-APBI) offers reduced irradiated volumes and radiation exposure while maintaining clinical outcomes, suggesting a favorable safety profile.15678
Is MRI-guided radiation therapy for breast cancer safe?
MRI-guided radiation therapy for breast cancer, such as prone whole breast irradiation, has been shown to result in lower rates of toxicity and reduced radiation exposure to the heart and lungs compared to other methods. Additionally, MRI-guided approaches can reduce the amount of healthy tissue exposed to radiation, potentially lowering the risk of long-term side effects.15678
Is MRI-guided Precision Prone Irradiation a promising treatment for breast cancer?
What makes MRI-guided radiation therapy for breast cancer unique compared to other treatments?
MRI-guided radiation therapy for breast cancer is unique because it uses MRI technology to precisely target the tumor, reducing the amount of healthy breast tissue exposed to radiation. This approach can potentially lower the risk of side effects and improve treatment accuracy by allowing better visualization of the tumor before and during each treatment session.1291011
What is the purpose of this trial?
The Investigators are investigating the potential role of MRI-guided Radiation Therapy for patients receiving breast radiotherapy in the prone position with a MRI-Linac radiotherapy system, the Precision Prone Irradiation (PPI) technique.Hypothesis: The investigators would like to hypothesize that breast radiation therapy using MRI-guided system including the MRI-Linac (Arm 2) is comparable to the current standard of treatment using conventional CT-based system (Arm 1), in terms of local control of the disease at 2 year time point.
Research Team
John Ng, M.D.
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for women over 50 with early-stage breast cancer (DCIS or Stage I) who've had a lumpectomy with clear margins. It's not for those who've had radiation on the same breast before, can't have an MRI, are more than 90 days post-surgery without chemo, or more than 60 days post-chemo.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 3000 cGy in 5 fractions partial breast radiotherapy with either CT-based or MRI-based system
Follow-up
Participants are monitored for safety and effectiveness after treatment, with annual follow-ups up to 10 years
Treatment Details
Interventions
- CT-guided Breast Irradiation
- MRI-guided Precision Prone Irradiation (PPI)
CT-guided Breast Irradiation is already approved in European Union, United States, Canada, Japan for the following indications:
- Breast cancer
- Early-stage breast cancer
- Locally advanced breast cancer
- Breast cancer
- Early-stage breast cancer
- Locally advanced breast cancer
- Ductal carcinoma in situ (DCIS)
- Breast cancer
- Early-stage breast cancer
- Locally advanced breast cancer
- Breast cancer
- Early-stage breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor